three
class
antivir
drug
approv
treatment
influenza
ion
channel
inhibitor
amantadin
rimantadin
neuraminidas
na
inhibitor
laninamivir
oseltamivir
peramivir
zanamivir
proteas
inhibitor
favipiravir
agent
avail
select
countri
agent
effect
treat
sign
symptom
influenza
patient
infect
suscept
virus
clinic
failur
demonstr
patient
infect
virus
primari
resist
ie
antivir
present
viru
initi
infect
patient
resist
may
emerg
cours
therapi
na
inhibitor
activ
nine
na
subtyp
recogn
natur
includ
highli
pathogen
avian
influenza
recent
lowpathogen
avian
influenza
virus
sinc
season
influenza
usual
acut
selflimit
ill
viral
clearanc
usual
occur
rapidli
due
innat
adapt
host
immun
respons
emerg
drugresist
variant
would
anticip
limit
effect
clinic
recoveri
otherwis
healthi
patient
demonstr
clinic
unfortun
immunocompromis
immunolog
host
young
children
infant
expos
novel
strain
like
mutat
confer
resist
emerg
therapi
resist
variant
may
also
result
clinic
signific
advers
outcom
factor
influenc
clinic
epidemiolog
import
drugresist
influenza
virus
includ
magnitud
phenotyp
resist
frequenc
rapid
emerg
stabil
abil
resist
variant
compet
wildtyp
viru
absenc
select
drug
pressur
effect
resist
mutat
viral
replic
compet
pathogen
transmiss
vivo
prior
replac
pandem
viru
circul
season
virus
season
contain
mutat
therefor
highli
resist
oseltamivir
retain
suscept
zanamivir
current
circul
virus
mutat
confer
inhibitor
resist
data
date
indic
inhibitor
resist
associ
worsen
viral
virul
atyp
influenza
enhanc
transmiss
sporad
virus
primari
resist
mutat
result
neuraminidas
inhibitor
resist
describ
na
mutat
confer
resist
clinic
isol
associ
reduc
infect
replic
pathogen
anim
model
influenza
featur
import
clinic
manag
individu
patient
also
key
factor
need
consid
health
author
govern
make
decis
regard
stockpil
antivir
respons
pandem
influenza
threat
concern
antivir
resist
particularli
na
inhibitor
dissuad
countri
develop
adequ
antivir
inventori
pandem
respons
frequenc
resist
emerg
therapi
higher
inhibitor
na
inhibitor
develop
resist
cours
therapi
common
among
initi
inhibitorsuscept
virus
past
mutat
one
five
amino
acid
gene
result
crossresist
amantadin
rimantadin
resist
emerg
therapi
neuraminidas
inhibitor
gener
remain
rare
circul
strain
b
virus
higher
rate
children
immunocompromis
patient
common
featur
patient
develop
resist
despit
ongo
therapi
highlevel
replic
longer
durat
replic
presenc
antivir
therapi
resist
neuraminidas
inhibitor
result
mutat
neuraminidas
gene
hemagglutinin
gene
specif
mutat
determin
degre
resist
neuraminidas
inhibitor
reduc
suscept
frequenc
magnitud
na
inhibitor
resist
vari
drug
viru
neuraminidas
type
subtyp
resist
demonstr
develop
cours
therapi
avian
virus
particularli
greater
frequenc
season
human
virus
compensatori
mutat
may
also
occur
improv
fit
transmiss
resist
virus
may
play
role
establish
persist
transmiss
demonstr
season
season
sever
new
class
antivir
mani
novel
mechan
action
current
undergo
develop
resist
mutat
identifi
mani
agent
vitro
passag
experi
clinic
evid
resist
emerg
still
infanc
follow
section
review
clinic
epidemiolog
data
antivir
resist
three
class
avail
antiinfluenza
agent
inform
experiment
anim
model
influenza
incorpor
supplement
limit
data
deriv
clinic
studi
ion
channel
allow
influx
proton
viral
particl
turn
facilit
uncoat
inhibitor
bind
ion
channel
limit
influx
proton
result
antivir
effect
sinc
protein
present
influenza
virus
inhibitor
activ
influenza
b
current
two
approv
ion
channel
inhibitor
amantadin
rimantadin
earli
studi
demonstr
influenza
variant
highlevel
resist
amantadin
rimantadin
could
select
laboratori
though
vitro
vivo
passag
viru
presenc
drug
studi
resist
help
determin
mechan
antivir
action
inhibitor
mutat
inhibitor
gene
one
five
commonli
recogn
site
posit
protein
human
virus
result
reduc
bind
inhibitor
enlarg
pore
diamet
function
pore
virus
mutat
preserv
presenc
inhibitor
resist
mutat
affect
transmiss
replic
fit
compar
wildtyp
virus
document
transmiss
persontoperson
well
establish
resist
affect
drug
class
equal
appear
persist
time
routin
treatment
inhibitor
document
influenza
resist
variant
emerg
frequent
clinic
implic
resist
becam
appar
studi
treat
children
high
frequenc
resist
emerg
document
subsequ
household
nurs
home
transmiss
drugresist
variant
implic
failur
drug
prophylaxi
adult
treat
inhibitor
resist
variant
detect
cours
ill
high
frequenc
resist
emerg
immunocompromis
patient
patient
hospit
influenza
children
recent
frequenc
inhibitor
resist
among
season
isol
low
sinc
though
preval
resist
inhibitor
among
circul
influenza
increas
global
major
global
resist
class
drug
resist
result
substitut
inhibitor
inhibitor
resist
also
document
sever
import
novel
strain
influenza
pandem
viru
clade
virus
swineorigin
resist
inhibitor
result
substitut
clade
resist
secondari
substitut
note
clade
virus
remain
suscept
inhibitor
sinc
circul
strain
influenza
current
resist
inhibitor
class
recommend
prevent
treatment
influenza
current
current
rapid
test
screen
identifi
presenc
inhibitor
resist
resist
may
diagnos
use
phenotyp
assay
gene
sequenc
phenotyp
assay
includ
plaqu
reduct
yield
reduct
elisa
util
growth
viru
cell
cultur
expos
rang
concentr
drug
interest
assay
wide
avail
pyrosequenc
method
rapid
analysi
mutat
gene
associ
resist
describ
use
sever
refer
laboratori
neither
assay
typic
avail
clinic
lab
result
clinician
reli
data
gener
group
activ
monitor
resist
among
circul
strainin
unit
state
activ
done
center
diseas
control
prevent
http
wwwcdcgovflu
professionalsantiviralsantiviraldrugresistancehtm
detect
inhibitor
resist
usual
reli
viru
isol
respiratori
sampl
suscept
test
viru
cell
cultur
sever
assay
describ
includ
plaqu
reduct
yield
reduct
elisa
follow
phenotyp
analysi
genotyp
inhibitor
resist
confirm
nucleotid
sequenc
analysi
gene
detect
characterist
mutat
genotyp
detect
accomplish
quickli
use
pcr
restrict
length
polymorph
rflp
analysi
rna
extract
respiratori
sampl
use
commerci
avail
endonucleas
discrimin
point
mutat
gene
greater
sensit
detect
resist
clone
describ
revers
transcriptionpolymeras
chain
reaction
amplif
rna
follow
sequenc
multipl
clone
recent
rapid
pyrosequenc
techniqu
shown
reliabl
highthroughput
method
detect
genotyp
resist
larg
number
commun
isol
histor
human
isol
influenza
initi
suscept
amantadin
rimantadin
even
licensur
inhibitor
low
level
primari
resist
commun
isol
see
tabl
began
chang
field
isol
virus
china
note
signific
increas
resist
inhibitor
possibl
relat
increas
use
overthecount
amantadin
emerg
sever
acut
respiratori
syndrom
sar
influenza
season
approxim
isol
china
hong
kong
nearli
unit
state
europ
show
resist
due
mutat
frequenc
increas
unit
state
season
sinc
clinic
isol
note
mutat
gene
confer
resist
inhibitor
tabl
spread
occur
despit
absenc
sustain
select
drug
pressur
possibl
resist
gene
incorpor
effici
spread
ha
antigen
variant
phylogenet
analys
gene
suggest
common
origin
virus
experi
clearli
indic
resist
mutat
reduc
transmiss
stabl
time
frequenc
resist
season
virus
increas
primarili
due
mutat
fortun
incid
primari
resist
declin
among
season
virus
oseltamivirresist
virus
predomin
season
viru
replac
pandem
viru
primarili
resist
inhibitor
gener
due
mutat
result
current
circul
strain
influenza
primarili
resist
inhibitor
class
drug
recommend
prevent
treatment
influenza
protein
show
consider
evolut
human
swine
virus
subtyp
virus
phylogenet
differ
protein
may
influenc
mutat
advantag
confer
inhibitor
resist
characterist
featur
swine
virus
circul
europ
sinc
presenc
mutat
well
isol
confer
resist
inhibitor
postul
role
swine
intermedi
host
emerg
novel
human
virus
direct
interspeci
transmiss
bird
may
anoth
mechan
reassort
event
lead
acquisit
gene
encod
resist
human
strain
although
initi
human
isol
highli
pathogen
avian
virus
hong
kong
inhibitor
suscept
resist
class
drug
becom
preval
clade
virus
resist
inhibitor
result
substitut
clade
resist
secondari
substitut
note
clade
virus
remain
suscept
inhibitor
isol
infect
human
also
mutat
confer
resist
inhibitor
studi
experiment
infect
anim
treat
human
document
common
emerg
resist
variant
cours
infect
progress
time
follow
treatment
approxim
amino
acid
substitut
resist
virus
occur
posit
found
posit
mutat
respons
resist
variant
recent
identifi
global
rapid
emerg
resist
variant
inhibitortr
patient
found
also
studi
experiment
infect
anim
studi
chicken
viru
resist
virus
detect
day
start
drug
administr
persist
thereaft
studi
ferret
inocul
human
influenza
viru
detect
inhibitor
resist
mutat
four
nine
amantadinetr
anim
day
inocul
instanc
two
gene
mutat
identifi
resist
variant
aris
commonli
rapidli
inhibitortr
children
adult
acut
influenza
tabl
one
studi
adult
found
resist
viru
could
detect
six
rimantadin
recipi
day
treatment
although
nasal
lavag
titer
lower
placebo
recipi
shed
suscept
viru
anoth
studi
found
adult
pediatr
household
member
receiv
rimantadin
shed
resist
viru
day
treatment
none
posit
test
day
later
larger
pediatr
trial
found
emerg
resist
viru
rimantadin
recipi
includ
still
viru
posit
day
compar
acetaminophen
recipi
resist
viru
detect
earli
day
one
child
usual
present
day
studi
japanes
children
treat
amantadin
found
season
follow
season
resist
viru
detect
day
cours
resist
children
rimantadin
hayden
et
al
adult
rimantadin
englund
et
al
immunocompromis
amantadin
rimantadin
saito
et
al
children
amantadin
shirashi
et
al
children
hospit
amantadin
variant
detect
frequent
children
children
anoth
studi
employ
sensit
molecular
clone
detect
method
found
mutat
confer
resist
hospit
children
immedi
amantadin
treatment
nine
children
resist
mutat
detect
clone
singl
sampl
sometim
mix
wildtyp
viru
random
studi
patient
hospit
influenza
receiv
either
rimantadin
alon
rimantadin
plu
nebul
zanamivir
rimantadineresist
viru
detect
rimantadin
monotherapi
patient
nonresist
variant
detect
patient
receiv
combin
therapi
resist
influenza
virus
may
shed
prolong
period
immunocompromis
host
serv
reservoir
nosocomi
transmiss
one
studi
adult
bone
marrow
transplant
acut
leukemia
patient
recov
resist
viru
inhibitortr
patient
patient
ill
shed
viru
day
median
time
first
last
viru
isol
day
rang
day
death
associ
influenza
occur
patient
resist
viru
compar
without
prolong
ill
note
sever
protract
shed
report
document
prolong
shed
resist
variant
immunocompromis
host
without
continu
drug
exposur
includ
one
transplant
scid
child
shed
week
one
adult
leukemia
patient
shed
resist
viru
week
therapi
anoth
case
report
document
recoveri
resist
viru
month
cessat
cours
amantadin
well
shed
mixtur
wildtyp
viru
variant
differ
resist
genotyp
heterogen
popul
resist
variant
sequenti
dual
mutat
found
sever
immunocompromis
host
one
stem
cell
transplant
recipi
shed
dualli
inhibitor
oseltamivirresist
viru
least
month
probabl
year
prolong
shed
resist
variant
immunocompromis
host
consist
genet
stabil
variant
observ
experiment
anim
model
amantadin
rimantadin
effect
postexposur
prophylaxi
ill
due
suscept
strain
household
contact
ill
index
case
given
concurr
treatment
tabl
contrast
two
studi
found
signific
reduct
secondari
influenza
ill
household
contact
receiv
either
amantadin
rimantadin
postexposur
prophylaxi
ill
index
case
receiv
treatment
drug
one
document
failur
prophylaxi
due
infect
drugresist
variant
like
transmit
treat
index
case
find
indic
strategi
use
inhibitor
index
case
treatment
postexposur
prophylaxi
household
avoid
transmiss
inhibitorresist
virus
well
document
nurs
home
outbreak
influenza
may
manifest
persist
increas
number
virusposit
patient
despit
amantadin
prophylaxi
recoveri
genotyp
resist
viru
multipl
patient
prophylaxi
patient
staff
receiv
drug
indic
ongo
transmiss
set
particularli
true
multipl
isol
less
commonli
observ
resist
variant
found
nine
isol
variant
one
nurs
home
outbreak
frequenc
instanc
amantadin
rimantadin
fail
control
outbreak
resist
emerg
well
defin
although
exist
studi
demonstr
rang
protect
efficaci
studi
demonstr
patient
develop
infect
resist
virus
typic
mutat
resid
longterm
care
inhibitor
use
outbreak
find
emphas
import
proper
isol
treat
person
use
na
inhibitor
treatment
ill
person
inhibitorresist
influenza
virus
appear
caus
typic
influenza
ill
without
obvious
enhanc
attenu
symptom
ill
occur
presenc
absenc
drug
find
indic
loss
antivir
effect
vivo
although
sever
progress
infect
resist
viru
note
immunocompromis
debilit
elderli
patient
like
marker
patient
underli
condit
virul
resist
viru
patient
inhibitorresist
viru
similar
risk
pneumonia
hospit
death
compar
wildtyp
ill
gene
mutat
appear
attenu
potenti
virul
human
influenza
virus
subtl
effect
biolog
fit
exclud
studi
date
occasion
patient
wildtyp
viru
replac
resist
variant
cessat
amantadin
note
avian
virus
revers
absenc
select
drug
pressur
suggest
diminish
replic
compet
resist
genotyp
howev
common
resist
variant
appar
loss
replic
compet
transmiss
studi
bird
ferret
influenza
virus
mutat
impact
virul
mortal
febril
respons
peak
nasal
viral
titer
nasal
inflammatori
cell
count
gener
appear
inhibitorresist
human
influenza
virus
emerg
vivo
differ
substanti
replic
abil
pathogen
drugsuscept
wildtyp
virus
resist
phenotyp
typic
retain
absenc
drug
treat
patient
emerg
resist
viru
may
associ
persist
viral
recoveri
studi
delay
resolut
ill
immunocompet
person
although
patient
resist
emerg
cours
therapi
somewhat
longer
time
resolut
symptom
fever
possibl
function
impair
still
rapid
recoveri
placebotr
patient
patient
may
worsen
symptom
viral
titer
resist
emerg
well
amantadin
rimantadin
share
suscept
resist
resist
one
inhibitor
confer
highlevel
crossresist
anoth
one
entir
class
compound
target
protein
differ
mechan
antivir
action
neuraminidas
inhibitor
proteas
inhibitor
discuss
retain
full
activ
inhibitorresist
virus
appropri
choic
prophylaxi
treatment
suspect
inhibitorresist
infect
clinic
studi
suggest
oseltamivir
zanamivir
success
termin
institut
outbreak
amantadin
resist
proven
highli
probabl
vitro
test
suggest
synthet
nucleosid
ribavirin
favipiravir
also
inhibitori
inhibitorresist
influenza
b
virus
therapeut
consider
combin
therapi
may
also
option
small
studi
random
hospit
adult
rimantadin
monotherapi
rimantadinenebul
zanamivir
combin
therapi
combin
arm
trend
less
cough
fewer
patient
detect
inhibitor
resist
mutat
cours
therapi
recent
tripl
combin
amantadin
oseltamivir
ribavirin
studi
vitro
vivo
infect
patient
appear
effect
inhibit
viral
replic
vitro
improv
outcom
vivo
initi
design
na
inhibitor
acceler
solv
xray
structur
na
cocrystal
chemic
compound
acid
dana
transit
state
analogu
na
substrat
sialic
acid
serv
scaffold
na
inhibitor
deriv
vitro
studi
determin
genet
antivir
resist
profil
na
inhibitor
zanamivir
oseltamivir
initi
shortli
develop
review
due
differ
drug
bind
interact
structur
differ
enzym
activ
site
na
inhibitor
show
vari
antivir
resist
profil
na
depend
viru
type
subtyp
review
sequenti
passag
cell
cultur
select
resist
variant
found
chang
ha
could
confer
resist
vitro
also
ha
chang
predomin
found
receptor
bind
site
thought
restor
function
balanc
ha
receptorbind
na
receptordestroy
properti
mechan
influenc
viral
hana
function
balanc
may
play
role
emerg
oseltamivirresist
virus
season
frequenc
possibl
import
resist
emerg
drug
administr
studi
larg
context
control
clinic
trial
conduct
late
serv
basi
approv
zanamivir
oseltamivir
recent
approv
laninamivir
peramivir
although
zanamivir
oseltamivir
avail
mani
countri
sinc
use
quit
limit
except
japan
influenza
pandem
clinic
import
antivir
resist
emerg
assess
compar
clinic
outcom
oseltamivirtr
patient
infect
suscept
oseltamivirresist
viru
influenza
season
retrospect
clinic
studi
dharan
et
al
show
patient
infect
oseltamivirsuscept
viru
n
significantli
fewer
day
fever
treat
oseltamivir
n
compar
nontreat
patient
n
p
contrast
patient
infect
oseltamivirresist
virus
n
benefit
oseltamivir
treatment
n
p
similar
find
report
studi
saito
et
al
reduct
fever
day
report
treat
oseltamivirsuscept
patient
p
patient
infect
oseltamivirresist
viru
strain
oseltamivirresist
viru
variant
na
amino
acid
chang
emerg
first
norway
season
abl
spread
rapidli
human
becam
domin
variant
suggest
oseltamivirresist
viru
abl
spread
easili
popul
wild
type
unexpect
vitro
vivo
anim
studi
claim
reduc
virul
transmiss
na
inhibitorresist
virus
begin
influenza
season
unlik
situat
inhibitor
cell
culturebas
assay
valid
detect
phenotyp
resist
clinic
isol
partli
differ
cellular
receptor
specif
human
respiratori
epithelium
avail
cell
cultur
type
review
addit
type
assay
labor
intens
requir
addit
viru
titrat
step
make
assay
unfavor
highthroughput
surveil
human
madindarbi
canin
kidney
mdck
cell
line
stabli
overexpress
human
increas
alpha
sialic
acid
may
overcom
first
limit
howev
cell
wide
util
date
challeng
broad
variat
morpholog
influenza
plaqu
differ
influenza
type
subtyp
reduc
sensit
yield
reduct
assay
na
enzym
inhibit
phenotyp
assay
therefor
prefer
assay
screen
clinic
relev
na
inhibitor
resist
mutat
influenza
antivir
resist
surveil
fluorometr
munana
chemiluminesc
nastar
type
phenotyp
assay
avail
assay
limit
necess
viru
propag
step
may
therefor
reliabl
detect
resist
subpopul
detect
hamedi
na
inhibitor
resist
standard
interpret
report
na
inhibitor
suscept
influenza
virus
clear
definit
formul
use
inhibitori
concentr
ic
concentr
drug
requir
inhibit
standard
amount
na
activ
foldchang
threshold
compar
median
virus
typesubtypelineag
show
normal
inhibit
besid
phenotyp
resist
assay
numer
genotyp
pcrbase
resist
assay
develop
detect
previous
identifi
antivir
resist
mutat
na
compar
phenotyp
assay
type
assay
rapid
easi
perform
allow
minor
variant
detect
quasispeci
requir
addit
viru
cultur
step
unknown
resist
pattern
newli
emerg
influenza
subtyp
novel
na
inhibitor
identifi
use
pcrbase
resist
assay
typic
na
mutat
confer
resist
depend
drug
na
subtyp
oseltamivir
base
number
confer
resist
wherea
common
antivir
resist
mutat
virus
tabl
differ
interact
among
drug
activ
enzym
site
vari
pattern
crossresist
found
particular
na
mutat
importantli
zanamivir
laninamivir
retain
full
inhibitori
activ
variant
either
mutat
partial
activ
variant
virus
also
crossresist
peramivir
antivir
resist
may
caus
singl
resist
mutat
combin
addit
mutat
may
enhanc
level
resist
andor
caus
multidrug
resist
ha
bind
effici
associ
suscept
na
inhibitor
affect
amino
acid
chang
receptor
bind
consequ
ha
mutat
look
clinic
isol
usual
compar
sequenc
preand
posttherapi
isol
instanc
examin
chang
receptor
affin
ha
variant
reduc
receptor
affin
show
crossresist
vitro
na
inhibitor
gener
retain
suscept
na
inhibitor
vitro
anim
model
except
influenza
season
oseltamivirresist
virus
circul
global
incid
circul
b
virus
de
novo
resist
na
inhibitor
low
sinc
approv
drug
tabl
recent
studi
virus
collect
global
collabor
nation
influenza
center
determin
ic
data
na
inhibitor
oseltamivir
zanamivir
peramivir
laninamivir
virus
show
highli
reduc
inhibit
least
one
four
drug
virus
reduc
inhibit
reduct
highli
resist
isol
pandem
influenza
virus
amino
acid
chang
n
singl
resist
viru
detect
carri
amino
acid
chang
two
influenza
b
virus
bvictoria
b
yamagata
detect
recent
global
observ
multicent
clinic
trial
iri
followup
sampl
influenzainfect
patient
admiss
clinic
n
genotyp
resist
detect
baselin
respiratori
specimen
influenza
b
virusinfect
patient
apart
virus
inherit
amino
acid
chang
patient
receiv
antivir
emerg
resist
oseltamivir
could
detect
treatment
case
children
age
n
case
amino
acid
chang
detect
two
oseltamivirtr
children
jackson
et
al
revers
wild
type
observ
yen
et
al
abbrevi
chang
compar
wild
type
decreas
absent
nr
report
day
fever
ferret
expos
parent
viru
greater
ferret
expos
mutant
viru
day
vs
day
respect
p
viru
infect
chang
emerg
posttreat
although
incid
na
inhibitorresist
virus
current
low
occasion
cluster
oseltamivirresist
influenza
virus
reason
concern
resist
zanamivir
report
due
amino
chang
presenc
mutat
howev
may
caus
artifact
propag
viru
madindarbi
canin
kidney
mdck
cell
cultur
regard
highli
pathogen
avian
influenza
virus
lowpathogen
avian
influenza
virus
suscept
na
inhibitor
like
influenza
virus
amino
acid
chang
found
human
avian
viru
sequenc
deposit
genbank
addit
marker
reduc
na
inhibitor
suscept
amino
acid
posit
found
human
avian
isol
although
chang
major
antivir
resist
pattern
found
highli
pathogen
avian
influenza
virus
isol
report
amino
acid
chang
caus
sevenfold
increas
ic
oseltamivir
zanamivir
respect
abbrevi
nai
neuraminidas
inhibit
cl
chemiluminesc
fa
fluoresc
sequenc
analysi
neuraminidas
gene
pcr
polymeras
chain
reaction
one
isol
ninefold
reduc
suscept
zanamivir
oseltamivir
compar
mean
inhibitori
concentr
influenza
b
strain
contain
mix
popul
includ
resist
variant
mutat
b
four
isol
na
defici
found
resist
na
inhibitor
cell
culturebas
assay
chang
also
observ
viru
isol
emerg
amino
acid
chang
lowpathogen
avian
influenza
virus
circul
china
sinc
caus
high
na
inhibitor
resist
oseltamivir
peramivir
reduc
resist
zanamivir
unlik
virus
carri
amino
acid
chang
viru
seem
much
attenu
chang
like
influenza
virus
na
inhibitor
resist
influenza
b
virus
current
low
nevertheless
sever
oseltamivirresist
b
virus
isol
treat
untreat
patient
antivir
resist
neuraminidas
may
caus
chang
residu
addit
also
influenza
b
virus
found
mutat
caus
twoto
threefold
increas
ic
oseltamivir
zanamivir
peramivir
natur
infect
oseltamivirresist
variant
detect
much
commonli
treat
children
adult
tabl
past
analysi
sampl
influenza
patient
treat
oseltamivir
outpati
indic
frequenc
resist
detect
adult
children
similar
observ
made
recent
iri
trial
oseltamivirtr
outpati
resist
develop
children
age
higher
level
replic
longer
durat
viru
shed
increas
chanc
develop
antivir
resist
compar
adult
two
studi
japanes
children
report
high
frequenc
oseltamivir
resist
emerg
oseltamivir
therapi
use
weightbas
dose
children
japan
contrast
unit
dose
countri
associ
lower
drug
exposur
young
children
postul
major
factor
higher
frequenc
resist
detect
studi
among
volunt
experiment
infect
viru
oseltamivirresist
variant
mutat
detect
two
subject
associ
appar
rebound
viral
replic
studi
found
oseltamivirtr
subject
less
like
placebo
late
viral
isol
show
revers
eggadapt
inoculum
viru
human
receptor
ha
genotyp
find
suggest
ha
mutat
reduc
affin
human
receptor
might
replic
advantag
virus
human
receptor
prefer
oseltamivir
use
human
interestingli
amino
acid
chang
ha
influenza
virus
prior
emerg
oseltamivirresist
viru
season
predict
facilit
emerg
amino
acid
chang
immunocompromis
individu
tend
suffer
influenza
longer
seriou
complic
otherwis
healthi
patient
sinc
immunocompromis
patient
like
acquir
influenza
show
rel
high
influenzaassoci
mortal
effect
antivir
crucial
patient
like
influenza
young
children
higher
level
replic
longer
durat
viru
shed
immunocompromis
patient
increas
chanc
develop
antivir
resist
sever
recent
clinic
studi
report
emerg
antivir
resist
among
treat
immunocompromis
patient
uncommon
recent
prospect
clinic
studi
aim
studi
antivir
resist
immunocompromis
patient
n
resist
preval
report
four
case
na
detect
rtpcr
influenza
virusinfect
patient
retrospect
studi
similar
rate
report
na
amino
acid
chang
describ
frequent
influenza
viru
pandem
case
report
antiviraltr
immunocompromis
patient
amino
acid
chang
posit
also
report
caus
increas
level
resist
oseltamivir
impact
therapi
unclear
moder
increas
oseltamivir
resist
howev
virus
combin
highli
resist
oseltamivir
vitro
past
emerg
resist
immunocompromis
patient
also
describ
influenza
influenza
b
virusinfect
patient
treat
oseltamivir
zanamivir
mutat
viral
ha
na
glycoprotein
fatal
case
influenza
pandem
season
epidem
patient
belong
tradit
highrisk
group
develop
sever
diseas
includ
young
children
elderli
immunocompromis
patient
given
high
mortal
morbid
moder
effect
current
antivir
rel
high
preval
resist
immunocompromis
patient
better
treatment
strategi
clearli
need
patient
influenza
season
thought
na
inhibitor
resist
develop
go
hand
hand
reduct
viru
fit
mathemat
model
predict
rel
transmiss
oseltamivirresist
variant
would
result
low
level
resist
virus
circul
commun
base
anim
experi
reduc
fit
replic
compet
certain
na
resist
mutat
appear
depend
viru
subtyp
resist
mutat
instanc
oseltamivirresist
influenza
viru
amino
acid
chang
transmit
infect
ferret
show
reduct
nasal
viru
titer
oseltamivirresist
mutant
howev
found
mutant
transmiss
wild
type
compar
nasal
viru
titer
donor
recipi
anim
influenza
viru
mutat
requir
higher
inoculum
infect
donor
ferret
infect
transmit
viru
contact
anim
delay
day
compar
wildtyp
viru
earli
outbreak
pandem
question
whether
oseltamivirresist
mutant
would
attenu
vitro
replic
vivo
pathogen
studi
perform
use
resist
isol
howev
answer
conflict
research
found
slight
attenu
earli
mutant
virus
other
find
differ
conflict
data
conclud
differ
wildtyp
pandem
viru
counterpart
close
call
mean
pathogen
transmiss
addit
compensatori
mutat
may
facilit
emerg
na
inhibitor
resist
mutat
caus
initi
loss
viru
fit
instanc
amino
acid
chang
virus
sever
permiss
amino
acid
chang
suggest
facilit
emerg
oseltamivir
resist
chang
amino
acid
chang
appear
season
increas
enzymat
properti
na
prior
introduct
amino
acid
chang
amino
acid
chang
maintain
high
na
express
vitro
reduc
singl
express
compensatori
role
amino
acid
chang
posit
assign
compens
loss
fit
due
oseltamivir
resist
mutat
observ
commun
cluster
virus
amino
acid
chang
seem
attenu
amino
acid
chang
either
virus
contain
addit
chang
chang
amino
acid
posit
mutat
may
also
permiss
effect
pediatr
studi
use
mgkg
dose
oseltamivir
shown
give
reduc
drug
exposur
rapid
clearanc
children
age
year
insuffici
drug
exposur
may
contribut
resist
emerg
studi
pattern
na
inhibitor
crossresist
vari
viru
type
subtyp
zanamivir
retain
inhibitori
activ
common
resist
variant
emerg
therapeut
use
oseltamivir
peramivir
zanamivir
fulli
inhibitori
oseltamivirresist
variant
possess
substitut
depend
viru
assay
zanamivir
partial
inhibitori
resist
variant
substitut
loss
suscept
compar
wild
type
controversi
role
peramivir
manag
variant
resist
oseltamivir
vitro
vivo
model
given
conflict
result
oseltamivir
inhibitori
mutat
influenza
b
na
confer
reduc
suscept
zanamivir
given
find
expert
recommend
use
zanamivir
treatment
patient
develop
resist
virolog
failur
oseltamivir
inhal
zanamivir
util
patient
variabl
success
studi
systemat
oseltamivirresist
infect
success
less
like
patient
influenza
pneumonia
intraven
zanamivir
util
frequent
patient
proven
suspect
resist
influenza
therapi
effect
patient
avail
data
preclud
assess
optim
role
intervent
given
sever
ill
mani
patient
convers
therapi
signific
prior
exposur
numer
intervent
na
inhibitor
zanamivir
dimer
prolong
durat
antivir
effect
topic
applic
current
develop
may
provid
na
inhibitor
prevent
perhap
treatment
altern
futur
ribavirin
would
also
expect
inhibitori
influenza
b
virus
resist
na
inhibitor
report
use
human
influenza
infect
due
variant
ribavirin
combin
na
inhibitor
exert
addit
synergist
antivir
activ
vitro
mice
experiment
infect
influenza
combin
oral
administ
ribavirin
peramivir
associ
improv
surviv
rel
ribavirin
alon
peramivir
alon
recent
studi
found
combin
ribavirin
oseltamivir
effect
ribavirin
alon
lethal
influenza
infect
superior
singl
agent
influenza
b
studi
ribavirinna
inhibitor
inhibitor
combin
see
warrant
determin
whether
strategi
offer
possibl
treat
sever
influenza
particularli
due
inhibitorresist
virus
recent
tripl
combin
amantadin
ribavirin
oseltamivir
studi
vitro
vivo
human
influenza
infect
given
promis
combin
prospect
phase
studi
ongo
assess
safeti
clinic
efficaci
combin
treatment
influenza
combin
therapi
demonstr
reduc
develop
resist
clinic
studi
therefor
may
benefit
popul
increas
risk
develop
resist
emerg
favipiravir
antivir
drug
phosphoribosyl
cellular
enzym
activ
form
rtp
select
inhibit
rnadepend
rna
polymeras
influenza
viru
highli
activ
season
strain
influenza
b
pandem
viru
highli
pathogen
avian
influenza
viru
isol
human
isol
swine
antivir
activ
virus
resist
amantadin
rimantadin
oseltamivir
zanamivir
addit
dualli
resist
virus
na
inhibitor
resist
studi
serial
pa
phenotyp
genotyp
pa
np
sequenc
detect
sequenc
analysi
though
demonstr
enrich
g
c
transvers
mutat
increas
mutat
frequenc
shift
nucleotid
profil
individu
np
gene
clone
drug
select
pressur
clinic
studi
publish
novel
compound
frequenc
resist
emerg
fulli
understood
point
drug
current
licens
japan
use
select
approv
ministri
health
studi
efficaci
ongo
rest
world
goal
seek
regulatori
approv
near
futur
recent
studi
report
develop
neutral
antibodi
specif
target
conserv
region
viru
ha
ha
bind
antibodi
elegantli
shown
xray
crystal
structur
haantibodi
protein
complex
antibodi
differ
recognit
site
target
sialic
acid
rb
globular
head
other
bind
stalk
region
stalk
region
conserv
differ
ha
subtyp
crossreact
immun
sever
influenza
subtyp
may
obtain
broadli
neutral
capac
although
antibodi
develop
conserv
region
ha
mutat
aris
antibodi
target
site
may
result
viral
escap
current
circul
strain
influenza
primarili
resist
inhibitor
gener
suscept
clinic
avail
neuraminidas
inhibitor
sporad
case
neuraminidas
inhibitor
resist
recogn
limit
region
transmiss
demonstr
resist
season
becam
widespread
influenza
season
lastli
na
inhibitor
resist
demonstr
emerg
therapi
highli
pathogen
avian
influenza
virus
infect
human
highest
frequenc
virus
region
world
current
limit
singl
class
drug
neuraminidas
inhibitor
manag
influenza
infect
risk
resist
could
emerg
result
global
spread
pose
seriou
threat
requir
develop
novel
agent
combin
lesson
learn
pandem
suggest
significantli
higher
frequenc
antivir
resist
emerg
pandem
viru
compar
interpandem
influenza
clinic
epidemiolog
implic
antivir
resist
futur
pandem
influenza
viru
predict
confid
result
great
progress
made
develop
global
system
rapidli
monitor
suscept
pattern
circul
strain
need
maintain
potenti
expand
includ
region
spars
surveil
surveil
resist
pattern
anim
may
give
earli
warn
futur
pandem
influenza
virus
number
unansw
question
remain
regard
antivir
drug
resist
influenza
virus
contemporari
nextgener
sequenc
possibl
understand
kinet
emerg
resist
minor
variant
popul
predomin
popul
given
host
data
inform
optim
time
screen
intervent
specif
risk
factor
beyond
gener
concept
immunocompromis
young
age
identifi
predict
emerg
resist
therapeut
perspect
optim
approach
includ
durat
therapi
benefit
combin
therapi
patient
sever
ill
predict
prolong
shed
need
care
studi
current
signific
gap
capac
test
specimen
resist
result
mani
patient
potenti
resist
may
miss
result
desper
need
suscept
assay
util
broadli
clinic
laboratori
lastli
need
ongo
expand
surveil
antivir
suscept
pattern
human
anim
influenza
virus
especi
commun
isol
countri
higher
antivir
use
resist
transmiss
highrisk
epidemiolog
set
given
current
pattern
antivir
suscept
circul
strain
inhibitor
util
prevent
treatment
influenza
neuraminidas
inhibitor
consid
whenev
therapi
indic
therapi
start
earli
possibl
improv
benefit
obtain
use
therapi
given
slightli
broader
activ
oseltamivirresist
variant
zanamivir
would
prefer
therapi
patient
proven
suspect
oseltamivirresist
influenza
novel
agent
optim
novel
mechan
action
need
develop
drug
advanc
stage
develop
includ
polymeras
inhibitor
favipiravir
receptordestroy
sialidas
nitazoxanid
neutral
antibodi
convalesc
plasma
need
studi
optim
treatment
patient
particularli
novel
highli
resist
virus
lastli
combin
antivir
studi
understand
abil
prevent
overcom
resist
clinic
